New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. Vogel

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. VogelПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Updates in treatments for HER2-positive GEAПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Optimizing adjuvant treatment in HR+/HER2- early breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

HER2 In Breast Cancer: Testing Guidelines and New Treatment ApproachesПодробнее

Get to know HER2-positive breast cancer and its targeted treatmentsПодробнее

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine ResistanceПодробнее

Future of breast cancer care: HER2 therapies in earlier settings & de-escalationПодробнее

Sequencing HER2-targeted therapies in breast cancerПодробнее

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer ptsПодробнее

Reduce the Risk of Recurrence with Nerlynx | Webinar on Therapeutic Decision-makingПодробнее

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

Diversity in Cancer Care | Metastatic Disease: Late Diagnosis & Increased Recurrence RatesПодробнее